FDA decision on MDMA - what it means for patients and the future of therapy

When the FDA refused to approve MDMA-assisted therapy for PTSD in August 2024, it was difficult news for thousands of patients - veterans, trauma survivors, individuals with treatment-resistant PTSD. A decade of clinical research, hundreds of millions of dollars in investment, results suggesting a therapeutic breakthrough - and yet: no. What does this decision mean in practice? Who now has access to this therapy? And what’s next for patients in Poland and Europe?

KEY INFORMATION
• Australia was the first country to approve MDMA-assisted therapy for PTSD in February 2023 (effective July 1, 2023) - patients have legal access through authorized psychiatrists.
• In the USA, expanded access (compassionate use) remains available for patients who have exhausted standard treatment methods.
• The FDA refusal is not a global verdict - Israel and Canada are conducting their own parallel access programs.
• W Europie jedynym zatwierdzonym regulacyjnie psychodelikiem klinicznym jest esketamina (Spravato) - zatwierdzona przez EMA w depresji lekoopornej.

What exactly did the FDA block - and what did it not block?

The FDA's refusal (Complete Response Letter) concerned the registration application from Lykos Therapeutics for the approval of MDMA as a component of therapy assisted by psychotherapy for PTSD. The FDA did not prohibit clinical trials, did not suspend expanded access programs, and did not challenge the phase 3 study results as fabricated. It prohibited one specific thing: the commercial introduction of this therapy into the healthcare system in the USA without conducting additional clinical research (Yazar-Klosinski et al., J Psychopharmacol, 2025).

This is an important distinction. Patients in the USA can still participate in clinical trials for MDMA - several active studies are listed on ClinicalTrials.gov. They can also apply for access through the expanded access program if they have exhausted standard therapeutic options and their condition justifies the risk of experimental treatment. It is a narrow path, but it exists.

Australia as a model of access - what is happening there since 2023?

The Australian Therapeutic Goods Administration (TGA) approved MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression in February 2023, effective July 1, 2023. Australia became the first country in the world to fully regulate these therapies for clinical practice - outpacing the USA, which is historically rare in clinical pharmacology.

The Australian model is strictly controlled. Therapy can only be conducted by authorized psychiatrists (Authorised Prescribers), and sessions must take place in approved clinical facilities. MDMA is reserved for PTSD, while psilocybin is for treatment-resistant depression. The cost of a full course of MDMA therapy in Australia in 2024 was estimated at 10,000-25,000 AUD (about 25,000-60,000 PLN) - making it accessible only to wealthy patients or those with private insurance.

We have noticed that the Australian regulatory model is, in a sense, a natural experiment for the rest of the world. If the safety and efficacy data collected in the first 2-3 years of clinical practice are positive, they may become an argument for the FDA and EMA when considering future registration applications - filling the gap that the FDA pointed out: the lack of data from the 'real world' outside of clinical protocol.

What about patients in Europe and Poland?

In Europe, no country has regulatory approval for MDMA or psilocybin for clinical use outside of trials. The European Medicines Agency (EMA) had not considered any registration application for these substances as of May 2026. The only psychedelic approved by the EMA is esketamine (Spravato) - the active enantiomer of ketamine, approved in 2019 for the treatment of treatment-resistant depression.

In Poland, esketamine (Spravato) has been reimbursed for specific indications since 2023. This is an important option for patients with treatment-resistant depression - although it does not cover PTSD. Patients with PTSD in Poland can access standard psychotherapy (PE, EMDR, CPT), medications (sertraline, paroxetine approved by the FDA/EMA for PTSD), and - as an experimental option - ketamine administered off-label in private clinics.

Citation capsule - access to therapy after FDA denial: Australia was the first country in the world to regulatory approve MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression (TGA, 2023). In the USA, expanded access remains possible but limited. The FDA's 2024 decision did not close the door to therapy - it postponed its broad availability by at least 5-6 years.

Table: Access to psychedelic therapy worldwide (as of 2025)

The following summary shows the current regulatory status of psychedelic therapies in key jurisdictions.

Why the FDA denied - key methodological objections

Understanding what exactly the FDA challenged is important for assessing the prospects of therapy. The FDA Advisory Committee (AdCom) met in June 2024 and voted 9:2 against approval - a rare outcome in the history of advisory committees for drugs with high social demand. The main objections concerned three areas.

First: the issue of blinding. In the MDMA vs placebo studies, most participants were able to guess which group they belonged to - because the subjective effects of MDMA are pronounced. This is a fundamental methodological limitation for studies of psychoactive substances, which the FDA finds difficult to accept without additional corrective data. Second: potential abuse in therapy. The committee expressed concerns about cases reported by study participants and ethical procedures in certain research centers conducting Lykos studies. Third: lack of real-world data - clinical trials are controlled conditions, and the FDA wanted to see how therapy works outside the laboratory, especially with different patient and therapist profiles (Yazar-Klosinski et al., J Psychopharmacol, 2025).

Co dalej - prognoza na 2025-2030

Several processes are ongoing in parallel, and each could change the landscape of psychedelic therapy in the coming years. Compass Pathways expects results from its phase 3 COMP360 study (psilocybin in treatment-resistant depression) in 2025-2026. If the data are positive and methodologically sound, a registration application to the FDA could be submitted around 2026-2027. The EMA would operate with a similar delay.

Lykos Therapeutics announced the preparation of a new clinical trial for MDMA in accordance with FDA requirements. Even optimistically assuming a quick start (2025) and efficient execution (3-4 years), a new registration application would reach the FDA around 2028-2029, with a decision around 2030. This is a long timeline for patients who need help today.

Reviewing comments from the psychiatric community after the FDA decision, we noticed a divide: some researchers view the denial as disappointing but methodologically justified - and expect that the forced corrections will ultimately make the therapy safer and better documented. Another part emphasizes that 'perfection is the enemy of good' and that thousands of patients are suffering while waiting for access to therapy that is likely effective. Both positions are understandable.

Frequently Asked Questions

What does the FDA denial mean for PTSD patients waiting for MDMA therapy?

Directly means a lack of broad availability in the USA in the coming years. Patients can participate in clinical trials, apply for expanded access, or consider therapy in Australia (legal since 2023). Standard treatment for PTSD - PE, EMDR, sertraline - remains the first choice recommended by the VA and APA. The context of the FDA decision is described more broadly in the article about the reasons for the FDA denial.

Can PTSD patients still access MDMA-assisted therapy?

In the USA through expanded access for patients who have exhausted standard methods. In Australia through authorized psychiatrists (cost 10,000-25,000 AUD per course). In Europe only within clinical trials. Active recruitments available on ClinicalTrials.gov under the term 'MDMA PTSD'.

How did the FDA denial affect MAPS as an organization?

MAPS as a non-profit separated from Lykos Therapeutics even before the denial. After August 2024, MAPS continues to fund academic research. Lykos underwent restructuring and is preparing a response to FDA requirements. The decision did not end the research program - it postponed its commercialization (MAPS, 2024).

Can other countries approve MDMA therapy independently of the FDA?

Yes - and they already have. Australia (TGA, 2023), Canada (Special Access Program), and Israel have their own access programs. National regulators evaluate data independently of the FDA, although the FDA's decision influences how other regulatory agencies perceive risk.

What are the alternative pathways to psychedelic therapy in Europe?

Legal options include: participation in clinical trials (ClinicalTrials.gov), esketamine (Spravato) for treatment-resistant depression approved by the EMA, off-label ketamine in private clinics in Poland and other EU countries, and traveling to Australia for authorized psilocybin or MDMA therapy.

What does this mean for psilocybin research after the FDA's rejection of MDMA?

Directly - nothing. Compass Pathways and USONA continue phase 3 psilocybin studies independently. The denial may prompt these companies to exercise even greater methodological diligence - which will ultimately strengthen the quality of the data. More about the neurological mechanism of psilocybin in the article about neuroplasticity and BDNF.

When might the FDA reconsider the application for MDMA therapy?

The realistic timeline for Lykos or another sponsor to reapply is at the earliest 2027-2028, with an FDA decision around 2029-2030. This requires conducting a new phase 3 study (3-5 years) and an FDA review (6-12 months). The pace depends on the availability of funding and the ability to recruit participants.

What were the main concerns of the FDA and the advisory committee regarding Lykos's application?

The FDA Advisory Committee (AdCom) voted 9:2 against approval in June 2024. Three main objections: the issue of blinding (participants guess the group due to the pronounced subjective effects of MDMA), concerns about ethical procedures in some Lykos research centers, and the lack of data from real clinical conditions outside of controlled protocol. The FDA did not challenge the study results as fabricated - it requested additional research meeting these requirements (Yazar-Klosinski et al., J Psychopharmacol, 2025).

This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04